Murray Stahl's ABBV Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 19,541 shares of AbbVie Inc. (ABBV) worth $4.46 M, representing 0.06% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in ABBV, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2015, adding 3,061 shares. Largest reduction occurred in Q3 2025, reducing 3,357 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -812 | Reduce 3.99% | 19,541 | $228.49 |
| Q3 2025 | -3,357 | Reduce 14.16% | 20,353 | $231.54 |
| Q2 2025 | -447 | Reduce 1.85% | 23,710 | $185.62 |
| Q1 2025 | -1,891 | Reduce 7.26% | 24,157 | $209.52 |
| Q4 2024 | +203 | Add 0.79% | 26,048 | $177.70 |
| Q3 2024 | +1,722 | Add 7.14% | 25,845 | $197.48 |
| Q2 2024 | +106 | Add 0.44% | 24,123 | $171.52 |
| Q1 2024 | -23 | Reduce 0.10% | 24,017 | $182.10 |
| Q4 2023 | -784 | Reduce 3.16% | 24,040 | $154.97 |
| Q3 2023 | -25 | Reduce 0.10% | 24,824 | $149.06 |
| Q2 2023 | -254 | Reduce 1.01% | 24,849 | $134.73 |
| Q1 2023 | -2,184 | Reduce 8.00% | 25,103 | $159.37 |
| Q3 2022 | +264 | Add 0.98% | 27,287 | $134.20 |
| Q2 2022 | -1,345 | Reduce 4.74% | 27,023 | $153.17 |
| Q1 2022 | -200 | Reduce 0.70% | 28,368 | $162.12 |
| Q3 2021 | -500 | Reduce 1.72% | 28,568 | $107.88 |
| Q2 2021 | +61 | Add 0.21% | 29,068 | $112.63 |
| Q1 2021 | -1,226 | Reduce 4.06% | 29,007 | $108.22 |
| Q4 2020 | -2,639 | Reduce 8.03% | 30,233 | $107.13 |
| Q3 2020 | +761 | Add 2.37% | 32,872 | $87.58 |
| Q2 2020 | -1,040 | Reduce 3.14% | 32,111 | $98.19 |
| Q1 2020 | +1,867 | Add 5.97% | 33,151 | $76.20 |
| Q4 2019 | +192 | Add 0.62% | 31,284 | $88.54 |
| Q3 2019 | +431 | Add 1.41% | 31,092 | $75.71 |
| Q2 2019 | +508 | Add 1.68% | 30,661 | $72.73 |
| Q1 2019 | +544 | Add 1.84% | 30,153 | $80.59 |
| Q4 2018 | +266 | Add 0.91% | 29,609 | $92.20 |
| Q3 2018 | -2,981 | Reduce 9.22% | 29,343 | $94.57 |
| Q2 2018 | +56 | Add 0.17% | 32,324 | $92.62 |
| Q1 2018 | -781 | Reduce 2.36% | 32,268 | $94.64 |
| Q4 2017 | -150 | Reduce 0.45% | 33,049 | $96.70 |
| Q3 2017 | -152 | Reduce 0.46% | 33,199 | $88.86 |
| Q2 2017 | -102 | Reduce 0.30% | 33,351 | $72.53 |
| Q1 2017 | -401 | Reduce 1.18% | 33,453 | $65.17 |
| Q4 2016 | -1,202 | Reduce 3.43% | 33,854 | $62.62 |
| Q3 2016 | +301 | Add 0.87% | 35,056 | $63.07 |
| Q2 2016 | -1,399 | Reduce 3.87% | 34,755 | $61.92 |
| Q1 2016 | +135 | Add 0.37% | 36,154 | $57.12 |
| Q4 2015 | +898 | Add 2.56% | 36,019 | $59.22 |
| Q3 2015 | +3,061 | Add 9.55% | 35,121 | $54.41 |
| Q2 2015 | -4 | Reduce 0.01% | 32,060 | $67.19 |
| Q1 2015 | -3,094 | Reduce 8.80% | 32,064 | $58.54 |
| Q4 2014 | -107 | Reduce 0.30% | 35,158 | $65.45 |
| Q3 2014 | -8 | Reduce 0.02% | 35,265 | $57.76 |
| Q2 2014 | -609 | Reduce 1.70% | 35,273 | $56.45 |
| Q1 2014 | +597 | Add 1.69% | 35,882 | $51.42 |
| Q4 2013 | +1,445 | Add 4.27% | 35,285 | $52.80 |
| Q3 2013 | +153 | Add 0.45% | 33,840 | $44.71 |
| Q2 2013 | +33,688 | Add 0.00% | 33,687 | $41.35 |
Murray Stahl's AbbVie Investment FAQs
Murray Stahl first purchased AbbVie Inc. (ABBV) in Q2 2013, acquiring 33,687 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held AbbVie Inc. (ABBV) for 51 quarters since Q2 2013.
Murray Stahl's largest addition to AbbVie Inc. (ABBV) was in Q2 2013, adding 33,687 shares worth $1.39 M.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 19,541 shares of AbbVie Inc. (ABBV), valued at approximately $4.46 M.
As of the Q4 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.06% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in AbbVie Inc. (ABBV) was 36,154 shares, as reported at the end of Q1 2016.